other material
confidence high
sentiment positive
materiality 0.85
Precigen reports positive Phase 1 PRGN-2012 data: 50% complete response in RRP patients
PRECIGEN, INC.
- 50% of RRP patients at Dose Level 2 achieved Complete Response, requiring no post-treatment surgeries.
- Median annual RRP surgeries dropped from 6.5 pre-treatment to 0.5 post-treatment at Dose Level 2.
- PRGN-2012 well-tolerated with no dose-limiting toxicities and no treatment-related Grade ≥3 adverse events.
- Preliminary cash, equivalents, and investments totaled ~$56M as of Dec 31, 2022; restricted cash ~$43.7M.
- Phase 2 study enrolling; 32 patients enrolled at Dose Level 2 to date; FDA discussions advancing for regulatory strategy.